A comparative effectiveness study examined whether primary cytoreductive surgery or neoadjuvant chemotherapy produces longer survival rates in patients with high-grade serous ovarian carcinoma.

Conferences

By Reuters Staff

LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.

Read More

Patients treated with intensity-modulated radiation therapy (IMRT) for cervical or endometrial cancer have fewer adverse events and experience better quality of life than those treated with conventional radiation therapy (RT), according to research presented at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting (September 25-28; Boston, MA).
-----

Read More

Prolonging platinum-free interval (PFI) by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer, according to clinical trial results presented at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7).

Read More

News

A comparative effectiveness study examined whether primary cytoreductive surgery or neoadjuvant chemotherapy produces longer survival rates in patients with high-grade serous ovarian carcinoma.
The US Food and Drug Administration (FDA) has granted regular approval for a drug as a maintenance treatment for women with recurrent ovarian cancer.
Relapse-free survival in ovarian and vulvar cancers may be significantly influenced by ABO blood group status.
The current recommended age of 65 years to stop cervical cancer screening should be reconsidered, according to researchers at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer.

Quiz

According to three recent studies, which cancer type's survival trends are not impacted by racial disparities?
Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?

Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?

-----

A. Rucaparib

B. Olaparib

C. Niraparib

D. Veliparib

-----

See the answer here.

Read More

Research in Review

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research published in Gynecologic Oncology (June 2017;145[3]:420-425).

-----

Related Content

Read More

The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent conference.

-----

Related Content

Read More

Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival (PFS) by almost 7 months, according to results of a study presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Slideshow

Within the past 3 months, the treatment landscapes for ovarian and cervical cancer have been evolving, with multiple updates to procedures, practices, and guidelines.
Subscribe to Ovarian Cancer